Loading clinical trials...
Loading clinical trials...
Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer
Conditions
Interventions
lapatinib
Locations
9
Japan
GSK Investigational Site
Ehime, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Okayama, Japan
GSK Investigational Site
Tochigi, Japan
GSK Investigational Site
Tokyo, Japan
Start Date
November 28, 2005
Primary Completion Date
April 1, 2009
Completion Date
April 1, 2009
Last Updated
January 31, 2019
NCT04915755
NCT00490139
NCT00272987
NCT05814224
NCT00251433
NCT01905592
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions